Skip to main content

Featured

Rising Tensions in the Gulf as Iran Threatens Oil Blockade

                                     An aerial view of the Iranian shores and Port of Bandar Abbas in the strait of Hormuz Iran has escalated regional tensions by declaring it will block all oil shipments from the Middle East if U.S. and Israeli attacks persist, prompting a stark warning from President Donald Trump of a far stronger American military response.  The Revolutionary Guards’ vow to halt “one litre of oil” from leaving the region has already rattled global markets, contributing to falling crude prices and surging equities as investors brace for potential disruption in the Strait of Hormuz—a vital chokepoint for global energy supplies. Trump responded by threatening unprecedented retaliation should Iran follow through, insisting the U.S. would strike “much harder” to ensure oil exports remain uninterrupted.  Despite the heated rhetoric, he expressed confid...
Post a Comment
Read more

article

Labels

Alzheimer’s vaccines get a boost from new drug approval

 

After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition. 

Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts. 

The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease. 

Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.


Labels:

Comments

Post a Comment